Entity Index
2 direct matches across organization references, story text, source records, and indexed tags.
These editor-confirmed paths connect a public entity mention in original reporting to a published follow-up. A link is not a truth verdict.
Despite multiple attempts, Eli Lilly has yet to reach a deal with Australia to list the diabetes and weight loss drug Mounjaro on the Pharmaceutical Benefits Scheme due to disagreements over pricing.
Showing 1-2 of 2 articles.
%22%2F%3E%0A%20%20%3Cpath%20d%3D%22M0%20706%20L1536%20432%20L1536%201024%20L0%201024%20Z%22%20fill%3D%22%23f3f5f7%22%20opacity%3D%220.18%22%2F%3E%0A%20%20%3Cpath%20d%3D%22M1060%200%20L1536%200%20L1536%201024%20L1250%201024%20Z%22%20fill%3D%22%23cc0000%22%20opacity%3D%220.38%22%2F%3E%0A%20%20%3Crect%20x%3D%2284%22%20y%3D%2288%22%20width%3D%22210%22%20height%3D%2218%22%20fill%3D%22%23cc0000%22%2F%3E%0A%20%20%3Ctext%20x%3D%2284%22%20y%3D%22164%22%20fill%3D%22%23ffffff%22%20font-family%3D%22Arial%2C%20Helvetica%2C%20sans-serif%22%20font-size%3D%2264%22%20font-weight%3D%22900%22%3EWORLD%3C%2Ftext%3E%0A%3C%2Fsvg%3E)
world
Health Minister Mark Butler confirms Ocrevus, Kesimpta, and Lemtrada will remain subsidised on the Pharmaceutical Benefits Scheme while a rapid review is conducted.
ABC Australia News | Jul 16, 2026, 3:42 PMShowing 1-2 of 2 articles.